JPMorgan Cuts Insmed Stock Price Target to $175.00 Amid Strong Quarterly Earnings
Insmed's stock price target has been cut to $175.00 by analysts at JPMorgan Chase & Co.
This comes after a recent review of the biopharmaceutical company's performance, where its quarterly earnings exceeded expectations.
The new target represents a potential upside of 29.55% from Insmed's current stock price of $135.09.